Nupur Nag

Dr. Nupur Nag

University of Melbourne
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2021 in Neurology
Verified
Journal Article
Open access
PDF file
SSSteve Simpson-Yap
Steve Simpson-Yap
EBEdward De Brouwer
Edward De Brouwer
TKTomas Kalincik
Tomas Kalincik
NRNick Rijke
Nick Rijke
JHJan A. Hillert
Jan A. Hillert
LPLiesbet Peeters
Liesbet Peeters
Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1–12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. Results Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01–2.41; aOR 2.43, 95% CI 1.48–4.02) and ICU admission (aOR 2.30, 95% CI 0.98–5.39; aOR 3.93, 95% CI 1.56–9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54–10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29–2.38; aOR 2.76, 95% CI 1.87–4.07) and ICU admission (aOR 2.55, 95% CI 1.49–4.36; aOR 4.32, 95% CI 2.27–8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09–12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13–3.07; aOR 2.88, 95% CI 1.68–4.92) and ICU admission (aOR 2.13, 95% CI 0.85–5.35; aOR 3.23, 95% CI 1.17–8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71–17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. Discussion Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.

1 May 2007 in Neuroscience
Verified
Journal Article
Closed access
NSN.A. Stearns
N.A. Stearns
LSL.R. Schaevitz
L.R. Schaevitz
HBH. Bowling
H. Bowling
Nupur NagNupur Nag
Nupur Nag
UBU.V. Berger
U.V. Berger
JBJ. Berger-Sweeney
J. Berger-Sweeney

1 May 2007 in Neurobiology of Disease
Verified
Journal Article
Closed access
Nupur NagNupur Nag
Nupur Nag
JBJoanne E. Berger-Sweeney
Joanne E. Berger-Sweeney

1 January 2009 in Behavioural Brain Research
Verified
Journal Article
Closed access
Nupur NagNupur Nag
Nupur Nag
JMJennifer M. Moriuchi
Jennifer M. Moriuchi
CPCassandra G.K. Peitzman
Cassandra G.K. Peitzman
BWBonnie C. Ward
Bonnie C. Ward
NKNancy H. Kolodny
Nancy H. Kolodny
JBJoanne E. Berger-Sweeney
Joanne E. Berger-Sweeney

1 June 2010 in Physiology & Behavior
Verified
Journal Article
Closed access
LSLaura R. Schaevitz
Laura R. Schaevitz
JMJennifer M. Moriuchi
Jennifer M. Moriuchi
Nupur NagNupur Nag
Nupur Nag
TMTiffany J. Mellot
Tiffany J. Mellot
JBJoanne Berger-Sweeney
Joanne Berger-Sweeney

26 February 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
YWYvette Wilson
Yvette Wilson
Nupur NagNupur Nag
Nupur Nag
PDPamela Davern
Pamela Davern
BOBrian Oldfield
Brian Oldfield
MMMichael J. McKinley
Michael J. McKinley
MMMark Murphy
Mark Murphy
We have used a transgenic approach to visualize functionally activated neurons and their projections. The transgenic mice contain a tau-lacZ fusion gene regulated by the promoter for c -fos , an immediate early gene that is rapidly induced in neurons after functional stimulation. Constitutive expression of β-galactosidase (β-gal), the lacZ product, was low and in accord with previous reports of c- fos expression. However, expression of β-gal in positive neurons was clearly in cell bodies, axons, and dendrites. Treatment of the mice with kainic acid, a strong inducer of c- fos expression, resulted in high induction of β-gal. β-gal was induced in the same defined populations of neurons in the brain as those that express c- fos after kainic acid induction. Furthermore, the pattern of β-gal expression within the neurons changed over time after kainic acid treatment. Early after kainate treatment, β-gal was found mainly in cell bodies; at later times, expression extended further along the neuronal processes. This expression pattern is consistent with induction and anterograde transport of the Fos-Tau-β-gal protein in the neurons. To test whether a functionally activated pathway could be visualized, transgenic mice were deprived of water, which activates nuclei involved in body fluid homeostasis. β-gal induction was traced in neurons and their processes in the lamina terminalis, in magnocellular neurons of the supraoptic and paraventricular nuclei, and in their projections to the posterior pituitary gland. This strategy allowed the mapping of an activated osmoregulatory pathway. This transgenic approach may have general application in the mapping of functionally activated circuitry in the brain.